アジア太平洋地域の肝線維症治療市場規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

Customize Your Report レポートをカスタマイズする Buy Now 今すぐ購入 Free Sample Report 無料サンプルレポート
Home Healthcare Asia Pacific Liver Fibrosis Treatment Market
Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Free Sample Report 無料サンプルレポート Inquire Before Buying 事前に問い合わせる Buy Now今すぐ購入

アジア太平洋地域の肝線維症治療市場規模、シェア、トレンド分析レポート – 業界概要と2032年までの予測

  • Healthcare
  • Published Report
  • Apr 2025
  • Asia-Pacific
  • 350 ページ
  • テーブル数: 775
  • 図の数: 42
  • Author : Sachin Pawar
Buy Now 今すぐ購入 Request for Sample 無料サンプルPDFをダウンロード
Nucleus Nucleus

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

サプライチェーンエコシステム分析は、現在DBMRレポートの一部です

アジア太平洋地域の肝線維症治療市場規模、シェア、トレンド分析レポート

Market Size in USD Billion

CAGR :  % Diagram

Chart Image USD 3.77 Billion USD 9.93 Billion 2024 2032
Diagram 予測期間
 2025 –2032
Diagram 市場規模（基準年）
 USD 3.77 Billion
Diagram Market Size (Forecast Year)
 USD 9.93 Billion
Diagram CAGR
 %
Diagram 主要市場プレーヤー
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

アジア太平洋地域の肝線維症治療市場：治療タイプ別（薬物療法および手術/療法）、ステージ別（F2、F1、F3、F4）、適応症別（非アルコール性脂肪肝炎（NASH）、B型およびC型肝炎誘発性線維症、アルコール性肝疾患（ALD）、自己免疫性肝疾患、遺伝性疾患、その他）、性別別（男性および女性）、エンドユーザー別（病院、専門医院、診療所、外来・研究センター、その他）、流通チャネル別（直接入札および小売販売） - 2032年までの業界動向と予測

アジア太平洋地域の肝線維症治療市場

アジア太平洋地域の肝線維症治療市場規模

  • アジア太平洋地域の 肝線維症治療市場は2024年に37億7000万米ドルと評価され、 2032年までに99億3000万米ドルに達すると予想されています。
  • 2025年から2032年の予測期間中、市場は主に自然健康ソリューションに対する消費者の意識の高まりにより、12.9％のCAGRで成長する可能性が高い。
  • この成長は、肝疾患の罹患率の上昇などの要因によって推進されています。さらに、価格の手頃さもアルコール消費量の増加を促しています。

アジア太平洋地域の肝線維症治療市場分析

  • 肝疾患の増加により、特にB型肝炎やC型肝炎などの疾患に対する効果的な治療法を必要とする患者数が増加しています。アルコール消費量の増加、不健康な食習慣、肥満率の増加などの要因により、これらの肝疾患と診断される人が増えています。
  • 肝障害が進行するにつれて、肝線維症を発症するリスクが高まり、効果的な治療選択肢を提供することが医療制度に大きな負担となります。この需要の高まりは、標的治療薬の開発と提供を促進し、医療提供者がこの疾患を管理するための革新的なソリューションを模索する中で、市場の成長を促進しています。
  • さらに、医療従事者や一般の人々の間で肝疾患に対する意識が高まったことにより、より早期の段階でスクリーニングと診断を受ける人が増えています。非侵襲性画像診断や血液検査などの診断技術の進歩により、肝線維症は病状の進行段階においてより早期に発見できるようになりました。この早期発見により、適切なタイミングでの介入が可能になり、肝線維症を効果的に改善または管理する革新的な治療法への需要が高まっています。
  • 例えば、2023年8月にNCBIが発表した論文によると、肝疾患は年間200万人の死亡原因となっており、全死亡数の4%（全世界で25人に1人）を占めています。また、肝臓関連の死亡の約3分の2は男性で発生しています。この憂慮すべき統計は、効果的な治療法の緊急性を強調し、肝疾患がもたらす重大な公衆衛生上の負担を浮き彫りにしています。医療制度と製薬会社が、肝線維症とその根本原因に特化した革新的な治療法の開発を優先するよう、さらなる動機付けとなっています。
  • その結果、製薬会社や医学研究者は新たな治療選択肢の開発に投資せざるを得なくなり、利害関係者が肝疾患とその関連合併症の発生率上昇に対抗することを目指す中で市場が推進されています。

レポートの範囲とアジア太平洋地域の肝線維症治療市場のセグメンテーション

属性

世界の肝線維症治療市場における主要な市場洞察

対象セグメント
  • 治療の種類別
    • 薬
    • 手術/治療
  • ステージ
    • F2
    • F1
    • F3
    • F4
  • 表示
    • 非アルコール性脂肪肝炎（NASH）
    • B型肝炎およびC型肝炎による線維化
    • アルコール性肝疾患（ALD）
    • 自己免疫性肝疾患
    • 遺伝性疾患
    • その他
  • 性別
    • 男
    • 女性
  • エンドユーザー
  • 病院
    • 専門クリニック
    • クリニック
    • 外来・研究センター
    • その他
  • 流通チャネル
    • 直接入札
    • 小売売上高

対象国
  • 北米
    • 私たち
    • カナダ
    • メキシコ
  • ヨーロッパ
    • ドイツ
    •  フランス
    •  英国
    •  イタリア
    •  スペイン
    •  スイス
    •  ロシア
    •  ベルギー
    •  オランダ
    •  七面鳥
    •  ポーランド
    •  スウェーデン
    •  ノルウェー
    •  デンマーク
    •  フィンランド
    •  その他のヨーロッパ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • シンガポール
    • タイ
    • インドネシア
    • マレーシア
    • 台湾
    • ニュージーランド
    • フィリピン
    • ベトナム
    • その他のアジア太平洋地域
  • 南アメリカ
    • ブラジル
    • アルゼンチン
    • 南アメリカのその他の地域
  • 中東およびアフリカ
    • 南アフリカ
    •  サウジアラビア
    •  アラブ首長国連邦
    •  エジプト
    •  イスラエル
    •  クウェート
    •  カタール
    •  オマーン
    •  その他の中東およびアフリカ

主要な市場プレーヤー
  • F. ホフマン・ラ・ロシュ社（スイス）
  • アボット（米国）
  • ラ レノン ヘルスケア プライベートLtd.（インド）
  • GENFIT SA（フランス）
  • マドリガル・ファーマシューティカルズ（米国）
  • アリゴス・セラピューティクス（米国）
  • ファイザー社（米国）
  • エナンタ・ファーマシューティカルズ社（米国）
  • ブリストル・マイヤーズ スクイブ社（米国）
  • バーテックス・ファーマシューティカルズ・インコーポレーテッド（米国）
  • 武田薬品工業株式会社（日本）
  • ヘピオン・ファーマシューティカルズ（米国）
  • エコセンス（フランス）
  • ガレクチン・セラピューティクス社（米国）
  • コナタス・ファーマシューティカルズ（米国）
  • Tvardi Therapeutics（米国）
  • バイキング・セラピューティクス（米国）
  • Calliditas Therapeutics AB (スウェーデン)
  • ノボメディックス（米国）
  • ガレクト・バイオテック（デンマーク）
  • ピラント・セラピューティクス社（米国）
  • サジメットバイオサイエンス（米国）
  • Gyre Therapeutics, Inc.（米国）
  • アケロ・セラピューティクス社（米国）
  • CureVac SE（ドイツ）
  • ノボノルディスクA/S（デンマーク）
  • イプセンファーマ（フランス）
  • AdAlta Limited（オーストラリア）
  • アレンティス・セラピューティクスAG（スイス）
  • ギリアド・サイエンシズ（米国）
  • アッヴィ社（米国）
  • メルク社（米国）
  • ノバルティスAG（スイス）
  • インターセプト・ファーマシューティカルズ社（米国）

市場機会
  • 肝線維症管理における新技術と先進治療
  • 肝線維症治療のためのパイプライン製品の進展
  • 主要企業間の戦略的合併と買収

付加価値データ情報セット

データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、輸出入分析、生産能力の概要、生産消費分析、価格動向分析、気候変動シナリオ、サプライチェーン分析、バリューチェーン分析、原材料/消耗品の概要、ベンダー選択基準、PESTLE分析、ポーター分析、規制枠組みも含まれています。

アジア太平洋地域の肝線維症治療市場動向

「肝疾患の罹患率の増加」

  • 肝疾患の罹患率の増加は、世界的に重大な健康問題として浮上しており、世界中の医療負担に大きく貢献しています。
  • 過度のアルコール摂取、肥満率の上昇、ウイルス性肝炎の感染、不健康な生活習慣などの要因により、脂肪肝疾患、肝硬変、肝臓がんなどの病気が急増しています。
  • 非アルコール性脂肪性肝疾患（NAFLD）の罹患率の増加は、特に糖尿病やメタボリックシンドロームとの関連が強く、憂慮すべき事態となっています。その結果、早期診断、効果的な治療法、そして公衆衛生への取り組みに対する需要が高まっています。この傾向は、肝疾患治療市場におけるイノベーションと成長を促進すると期待されています。

アジア太平洋地域の肝線維症治療市場の動向

ドライバー

「アルコール消費量の増加」

  • アルコール消費量の増加は、肝疾患、特にアルコール性肝疾患（ALD）の発生率と直接相関しているため、世界の肝線維症治療市場に大きく貢献しています。
  • より多くの人々が定期的に、より大量にアルコールを摂取するにつれて、肝線維症や肝硬変などの肝臓関連の合併症を発症するリスクが大幅に増加する。
  • 慢性アルコール依存症は、肝臓が繰り返し損傷と修復を受けることで炎症、脂肪蓄積、そして最終的には線維症を引き起こします。
  • アルコール関連の肝疾患の罹患率の増加により、肝障害を軽減し、患者の転帰を改善するための効果的な治療法と管理戦略が緊急に求められています。

例えば、

  • 2024年10月、International Journal of Mental Health Systemsに掲載された論文によると、アルコール消費率はベースライン時と追跡調査時でそれぞれ54.5%と47.7%でした。さらに、男性の12%が新たに飲酒を始めたと報告しています。このアルコール消費率の上昇は、世界的に肝線維症の発生率の上昇につながり、市場の成長に影響を与える可能性があります。
  • STATによると、2024年6月現在、アルコール関連の死亡者数は増加傾向にあり、専門家は特に若者と女性の増加を懸念している。米国では、2019年から2020年にかけてアルコール関連の死亡者が25.5%増加し、全死亡者の3%を占めた。さらに、アルコール関連の死亡者数の増加幅が最も大きかったのは25～34歳と35～44歳の年齢層で、両年齢層で37%以上増加した。
  • さらに、特に若年層におけるアルコール消費の社会的受容と正常化の増加は、問題をさらに悪化させ、肝線維化のリスクがある人の数の増加につながっています。
  • この傾向は、肝線維症治療市場の成長を促進し、アルコール消費を減らし、肝疾患を予防することを目的とした公衆衛生イニシアチブの重要性を強調しています。

機会

「肝線維症管理における新技術と先進治療」

  • 遺伝子治療、分子標的治療、生物学的製剤などの新興技術は治療の状況を一変させている。

  • 近年のイノベーションは、線維化の進行経路を特異的に標的とする薬剤、例えばFXRアゴニスト、TGF-β阻害薬、抗炎症薬に焦点を当てています。さらに、エラストグラフィーなどの非侵襲的診断ツールによって、早期発見率が向上しています。

  • これらの進歩により、NASH（非アルコール性脂肪肝炎）や肝硬変などの症状に対するより効果的で個別化された治療が可能になり、患者の転帰が改善されます。

  • 2024年2月、Springer Nature誌に掲載された論文では、肝線維化の診断と阻害に関する新たなアプローチが概説されています。その進歩には、非侵襲性バイオマーカー、イメージング技術、間葉系幹細胞などの細胞療法が含まれます。ピルフェニドンやオベチコール酸などの有望な抗線維化薬に加え、組織工学、ナノテクノロジー、マイクロ流体モデルにおける革新は、個別化された精密治療の可能性を示しています。

  • 2021年9月のNCBIの記事では、肝線維症治療における新興技術は、肝星細胞の活性化といった分子経路を標的とした先進的な治療法に焦点を当てていることが強調されています。遺伝子治療、生物学的製剤、低分子阻害剤、非侵襲性診断といった革新により、早期発見と治療が向上します。幹細胞療法と組織工学もまた、線維症の改善と回復の促進に期待が寄せられています。

  • 治療戦略と診断技術の継続的な進化により、肝線維症の治療法は急速に進歩している。

  • これらのイノベーションは、肝疾患のより良い管理に希望をもたらし、患者がより効果的で個別化された治療を受け、副作用が少ないことを保証し、最終的には世界の健康成果を向上させる。

拘束/挑戦

「肝疾患に対する認識の不足」

  • 肝疾患に対する認識の低さは、早期診断と適切な介入を妨げます。多くの人は肝疾患のリスク要因や症状を認識しておらず、漠然とした病気の兆候を、それほど深刻ではない他の疾患のせいにしてしまうことがよくあります。
  • この知識不足により、肝線維症や肝硬変などの病気が進行するまで医療相談が遅れ、治療の選択肢がより複雑になり、効果も低下する。
  • その結果、診断が遅れると治療の成功率が低下し、タイムリーな治療を求める患者層が制限され、市場全体の成長が制限される。

例えば、

  • 2024年4月、ルピン氏は、患者は病気が重篤な段階に達するまで自分の病状に気づかないことから、肝臓の健康に関する認識、検出、そして管理へのアプローチを緊急に見直す必要があると述べました。しかし、肝臓の健康管理における大きな障害は、肝疾患とその関連リスク要因に関する理解が限られていることにあります。
  • 2021年7月、5つの全国健康栄養調査（National Health and Nutrition Examination Survey）から11,700人の成人（18歳以上）を対象とした調査によると、米国のNAFLD（非アルコール性脂肪性肝疾患）の成人の約96%が、特に若年成人において、肝疾患に気づいていませんでした。したがって、肝臓の健康に関する意識向上と教育は、患者の転帰を改善し、肝線維症の管理と治療市場拡大へのより積極的なアプローチを促進するために不可欠です。
  • 2021年1月、シュプリンガー・ネイチャーは、「2型糖尿病患者における肝臓障害の認識不足」と題した研究論文で実施された研究分析の対象となった825人の患者のうち、脂肪肝患者の8.1%（95%信頼区間5.1%～12.7%）が肝疾患を認識していたと報告しました。さらに、米国の成人2型糖尿病患者を対象とした全国規模の代表サンプルでは、​​進行した肝線維症の有病率が高く、進行した線維症患者のうち、何らかの肝疾患を認識している患者は20%未満です。
  • 認知度の低さは、患者の治療成果を阻害し、早期に医療サービスを受ける人の数を減らすことで市場の成長を阻害します。
  • したがって、肝臓の健康に関する意識と教育を高めることは、早期診断の改善、治療効果の向上、そして最終的には肝線維症治療のより堅調な市場を育成するために極めて重要である。

世界の肝線維症治療市場の展望

市場は、製品タイプ、処理、供給源、用途、投与経路、購入方法、年齢層、性別、エンドユーザー、流通チャネルに基づいてセグメント化されています。

セグメンテーション

サブセグメンテーション

治療の種類別
  • 治療の種類
    • 薬
    • 手術/治療

ステージ別
  • ステージ
    • F2
    • F1
    • F3
    • F4

適応症別
  • 表示
    • 非アルコール性脂肪肝炎（NASH）
    • B型肝炎およびC型肝炎による線維化
    • アルコール性肝疾患（ALD）
    • 自己免疫性肝疾患
    • 遺伝性疾患
    • その他。

エンドユーザー別
  • エンドユーザー
    • 病院
    • 専門クリニック
    • クリニック
    • 外来・研究センター
    • その他

流通チャネル別
  • 流通チャネル
    • 直接入札
    • 小売売上高

アジア太平洋地域の肝線維症治療市場の地域分析

「中国はメインフレーム市場における支配的な地域です」

  • 中国は、その強力な医療インフラ、肝臓関連疾患の高い罹患率、早期診断と介入戦略への強い重点により、アジア太平洋地域の肝線維症治療市場をリードしています。
  • この国は、広範な医療保険、確立された償還政策、そして非侵襲的な診断と治療の選択肢に対する需要の高まりから恩恵を受けている。
  • 中国の臨床研究におけるリーダーシップと肝臓疾患啓発キャンペーンへの積極的な参加が市場の成長をさらに支えている。
  • 先進的な治療法の導入の増加、患者の意識の高まり、そして慢性肝疾患への取り組みに対する政府の取り組みが、この地域におけるドイツの優位性に貢献している。

「中国は最高の成長率を記録すると予測されている」

  • 中国はまた、線維症バイオマーカーの継続的な革新、製薬会社による研究開発投資の増加、アルコール関連および非アルコール性脂肪性肝疾患の増加率に支えられ、最も急速に成長している市場でもあります。
  • これらの要因により、中国はアジア太平洋地域における肝線維症治療の中心拠点としての地位を確立し、同地域で最大かつ最も急速に拡大している市場となっています。

アジア太平洋地域の肝線維症治療薬市場シェア

市場競争環境は、競合他社ごとに詳細な情報を提供します。企業概要、財務状況、収益、市場ポテンシャル、研究開発投資、新規市場への取り組み、アジア太平洋地域におけるプレゼンス、生産拠点・設備、生産能力、強みと弱み、製品投入、製品群の幅広さ、アプリケーションにおける優位性などの詳細が含まれます。上記のデータは、各社の市場への注力分野にのみ関連しています。

市場で活動している主要なマーケットリーダーは次のとおりです。

  • F. ホフマン・ラ・ロシュ社（スイス）
  • アボット（米国）
  • ラ レノン ヘルスケア プライベートLtd.（インド）
  • GENFIT SA（フランス）
  • マドリガル・ファーマシューティカルズ（米国）
  • アリゴス・セラピューティクス（米国）
  • ファイザー社（米国）
  • エナンタ・ファーマシューティカルズ社（米国）
  • ブリストル・マイヤーズ スクイブ社（米国）
  • バーテックス・ファーマシューティカルズ・インコーポレーテッド（米国）
  • 武田薬品工業株式会社（日本）
  • ヘピオン・ファーマシューティカルズ（米国）
  • エコセンス（フランス）
  • ガレクチン・セラピューティクス社（米国）
  • コナタス・ファーマシューティカルズ（米国）
  • Tvardi Therapeutics（米国）
  • バイキング・セラピューティクス（米国）
  • Calliditas Therapeutics AB (スウェーデン)
  • ノボメディックス（米国）
  • ガレクト・バイオテック（デンマーク）
  • ピラント・セラピューティクス社（米国）
  • サジメットバイオサイエンス（米国）
  • Gyre Therapeutics, Inc.（米国）
  • アケロ・セラピューティクス社（米国）
  • CureVac SE（ドイツ）
  • ノボノルディスクA/S（デンマーク）
  • イプセンファーマ（フランス）
  • AdAlta Limited（オーストラリア）
  • アレンティス・セラピューティクスAG（スイス）
  • ギリアド・サイエンシズ（米国）
  • アッヴィ社（米国）
  • メルク社（米国）
  • ノバルティスAG（スイス）
  • インターセプト・ファーマシューティカルズ社（米国）

アジア太平洋地域の肝線維症治療市場の最新動向

  • ギリアド・サイエンシズは2024年6月、ミラノで開催された2024年欧州肝臓学会（EASL）において、原発性胆汁性肝管炎（PBC）、B型肝炎（HBV）、デルタ肝炎ウイルス（HDV）などの肝疾患に焦点を当てた新たな研究を発表しました。主要な発表には、PBCに対するセラデルパルに関するASSURE試験の長期データ、HBV肝癌予防のためのテノホビルの結果、HDVに対するヘプクルデックスに関するMYR204試験およびMYR301試験の知見が含まれます。この研究は、肝疾患の治療選択肢の進歩に対するギリアドのコミットメントを強調するものです。
  • 2024年10月、インターセプト・ファーマシューティカルズ社は、原発性胆汁性胆管炎（PBC）治療における人種差と格差の調査に向けた継続的な取り組みについて発表しました。同社は、PBCの診断、治療、管理において、様々な集団がそれぞれ異なる課題に直面する可能性があることに取り組んでいます。これらの格差を調査することで、インターセプトはすべての患者が治療にアクセスし、治療成績を向上させることを目指しており、線維化を含む肝疾患の効果的な治療への障壁を低減できる可能性があります。
  • 2022年11月、米国食品医薬品局（FDA）は、12歳以上の小児代償性肝疾患患者における慢性B型肝炎ウイルス（HBV）感染症の治療薬として、ベムリディ（テノホビルアラフェナミド）を承認しました。この承認は、2016年に成人の慢性HBV感染症患者に最初に承認されたベムリディの適応拡大となります。この承認は、この若年患者群におけるベムリディの有効性と安全性を実証した第2相臨床試験に基づいています。
  • 2022年9月、ギリアド・サイエンシズは、免疫抑制受容体を標的としたアゴニストによる免疫バランスの回復に注力する英国を拠点とするバイオテクノロジー企業、ミロバイオの買収を完了しました。買収額は約4億500万ドルで、ギリアドはミロバイオの創薬プラットフォームと免疫抑制受容体アゴニストのポートフォリオを獲得します。ミロバイオの主力抗体MB272は、免疫細胞を標的として炎症性免疫反応を抑制するもので、現在第1相臨床試験を実施中です。この買収により、ギリアドは慢性免疫介在性疾患への取り組みを強化します。
  • 2021年3月、ギリアド・サイエンシズとノボ ノルディスクは、非アルコール性脂肪肝炎（NASH）治療における提携を拡大し、第2b相臨床試験を開始しました。この試験では、ノボ ノルディスクのGLP-1受容体作動薬であるセマグルチドと、ギリアドのシロフェキソール（FXR作動薬）およびフィルソコスタット（ACC阻害薬）の併用療法の安全性と有効性を、NASHによる肝硬変患者において検証します。本試験では、肝線維化とNASHの症状緩和に対する治療効果を評価し、2021年後半に患者登録を開始する予定です。

SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

Sample Image 画像をクリックすると拡大します
  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY

4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY

4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY

4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY

4.3 EPIDEMIOLOGY

4.3.1 INCIDENCE OF ALL BY GENDER

4.3.2 TREATMENT RATE

4.3.3 TREATMENT RATE

4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.3.5 PATIENT TREATMENT SUCCESS RATES

4.4 MARKETED DRUG ANALYSIS

4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.5.1 PATIENT FLOW DIAGRAM

4.5.2 KEY PRICING STRATEGIES

4.5.3 KEY PATIENT ENROLLMENT STRATEGIES

5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF LIVER DISEASES

6.1.2 RISING CONSUMPTION OF ALCOHOL

6.1.3 RISING LIVER TRANSPLANTATION RATES

6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH

6.2 RESTRAINTS

6.2.1 LIMITED AWARENESS OF LIVER DISEASES

6.2.2 REGULATORY CHALLENGES

6.3 OPPORTUNITIES

6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT

6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT

6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS

6.4 CHALLENGES

6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS

6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE

7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 ANTIVIRAL AGENTS

7.2.1.1 VELPATASVIR/SOFOSBUVIR

7.2.1.2 TENOFOVIR

7.2.1.3 LEDIPASVIR/SOFOSBUVIR

7.2.1.4 SOFOSBUVIR

7.2.1.5 ENTECAVIR

7.2.2 ANTIFIBROTIC AGENTS

7.2.2.1 OBETICHOLIC ACID

7.2.2.2 TGF-Β INHIBITORS

7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS

7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS

7.2.2.5 OTHERS

7.2.3 ANTI-INFLAMMATORY DRUGS

7.2.3.1 CORTICOSTEROIDS

7.2.3.1.1 PREDNISONE

7.2.3.1.2 DEXAMETHASONE

7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS

7.2.3.2.1 INFLIXIMAB

7.2.3.2.2 ETANERCEPT

7.2.3.3 INTERLEUKIN (IL) INHIBITORS

7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)

7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)

7.2.4 IMMUNOSUPPRESSANTS

7.2.4.1 MYCOPHENOLATE MOFETIL

7.2.4.2 TACROLIMUS

7.2.4.3 CYCLOSPORINE

7.2.5 MARKETED DRUGS

7.2.5.1 VELPATASVIR/SOFOSBUVIR

7.2.5.2 TENOFOVIR

7.2.5.3 LEDIPASVIR/SOFOSBUVIR

7.2.5.4 OBETICHOLIC ACID (OCA)

7.2.5.5 SOFOSBUVIR

7.2.5.6 PIRFENIDONE

7.2.5.7 OTHERS

7.2.6 PIPELINE DRUGS

7.2.7 BRANDED DRUGS

7.2.7.1 EPCLUSA

7.2.7.2 VIREAD AND VEMLIDY

7.2.7.3 OCALIVA

7.2.7.4 HARVONI

7.2.7.5 SOVALDI

7.2.7.6 BARACLUDE

7.2.7.7 ACTOS

7.2.7.8 OTHERS

7.2.8 GENERIC DRUGS

7.2.9 ORAL

7.2.10 PARENTERAL

7.2.11 OTHERS

7.3 SURGERY/THERAPY

7.3.1 LIVER TRANSPLANTATION

7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)

7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)

7.3.4 SPLIT LIVER TRANSPLANTATION

7.3.5 DOMINO LIVER TRANSPLANT

7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES

7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)

7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)

7.3.6.3 LIVER ABLATION PROCEDURES

7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)

7.3.6.3.2 MICROWAVE ABLATION (MWA)

7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)

7.3.7.1 SEGMENTAL RESECTION

7.3.7.2 LOBECTOMY

7.3.7.3 WEDGE RESECTION

7.3.8 CELL-BASED THERAPY

7.3.8.1 STEM CELL THERAPY

7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)

7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)

7.3.8.2 GENE THERAPY

7.3.8.2.1 CRISPR-BASED LIVER REGENERATION

7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS

7.3.8.2.3 SIRNA-BASED THERAPIES

7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS

7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS

7.3.8.2.4.2 EMRICASAN

7.3.8.2.4.3 PENTOXIFYLLINE

7.3.8.2.4.4 LOSARTAN

7.3.8.2.4.5 METHYL FERULIC ACID

7.3.8.2.4.6 OTHERS

7.4 OTHERS

8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES

8.1 OVERVIEW

8.2 F2

8.3 F1

8.4 F3

8.5 F4

9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION

9.1 OVERVIEW

9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)

9.3 HEPATITIS B & C-INDUCED FIBROSIS

9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS

9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS

9.4 ALCOHOLIC LIVER DISEASE (ALD)

9.5 AUTOIMMUNE LIVER DISEASES

9.5.1 AUTOIMMUNE HEPATITIS (AIH)

9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)

9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)

9.6 GENETIC DISORDERS

9.6.1 HEMOCHROMATOSIS

9.6.2 WILSON’S DISEASE

9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY

9.7 OTHERS

10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER

10.1 OVERVIEW

10.2 MALE

10.2.1 40-55 YEARS

10.2.2 ABOVE 55 YEARS

10.2.3 BELOW 40 YEARS

10.3 FEMALE

10.3.1 ABOVE 55 YEARS

10.3.2 40-55 YEARS

10.3.3 BELOW 40 YEARS

11 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 PUBLIC HOSPITALS

11.2.2 PRIVATE HOSPITALS

11.3 SPECIALTY CLINICS

11.3.1 HEPATOLOGY CLINICS

11.3.2 GASTROENTEROLOGY CLINICS

11.4 CLINICS

11.5 AMBULATORY AND RESEARCH CENTERS

11.6 OTHERS

12 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.2.1 RETAIL SALES

12.2.1.1 HOSPITAL PHARMACY

12.2.1.2 RETAIL PHARMACY

12.2.1.3 ONLINE PHARMACY

13 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY REGION

13.1 OVERVIEW

13.2 ASIA-PACIFIC

13.2.1 CHINA

13.2.2 JAPAN

13.2.3 INDIA

13.2.4 SOUTH KOREA

13.2.5 AUSTRALIA

13.2.6 SINGAPORE

13.2.7 THAILAND

13.2.8 INDONESIA

13.2.9 MALAYSIA

13.2.10 TAIWAN

13.2.11 NEW ZEALAND

13.2.12 PHILIPPINES

13.2.13 VIETNAM

13.2.14 REST OF ASIA-PACIFIC

14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 GILEAD SCIENCES, INC.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT/NEWS

16.2 ABBVIE, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENT

16.3 MERCK & CO, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 NOVARTIS AG

16.4.1 COMPANY SNAPSHOTS

16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 PIPELINE PRODUCT PORTFOLIO

16.4.6 RECENT DEVELOPMENT

16.5 INTERCEPT PHARMACEUTICALS, INC.

16.5.1 COMPANY SNAPSHOTS

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 PIPELINE PRODUCT PORTFOLIO

16.5.6 RECENT NEWS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 1.1.5 RECENT DEVELOPMENT

16.7 ALIGOS THERAPEUTICS

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENT

16.8 ALNICHE LIFE SCIENCES PVT. LTD.

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 ALENTIS THERAPEUTICS AG

16.9.1 COMPANY SNAPSHOT

16.9.2 PIPELINE PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENT

16.1 ADALTA LIMITED

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PIPELINE PRODUCT PORTFOLIO

16.10.4 RECENT NEWS

16.11 AKERO THERAPEUTICS, INC.

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PIPELINE PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BRISTOL-MYERS SQUIBB

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CALLIDITAS THERAPEUTICS AB

16.13.1 COMPANY SNAPSHOT

16.13.2 PIPELINE PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 CUREVAC SE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 CONATUSPHARMA

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT/NEWS

16.16 ENANTA PHARMACEUTICALS, INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 ECHOSENS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT/NEWS

16.18 F. HOFFMANN-LA ROCHE LTD

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 COMPANY SHARE ANALYSIS

16.18.4 PRODUCT PORTFOLIO

16.18.5 RECENT DEVELOPMENT

16.19 GALECTO BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PIPELINE PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT/NEWS

16.2 GALECTIN THERAPEUTICS, INC.

16.20.1 COMPANY SNAPSHOTS

16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS

16.20.3 PIPELINE PRODUCT PORTFOLIO

16.20.4 RECENT DEVELOPMENT

16.21 GYRE THERAPEUTICS, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT/NEWS

16.22 GENFIT SA

16.22.1 COMPANY SNAPSHOTS

16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.22.3 PIPELINE PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 HEPION PHARMACEUTICALS

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PIPELINE PORTFOLIO

16.23.4 RECENT DEVELOPMENT

16.24 IPSEN PHARMA

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PIPELINE PRODUCT PORTFOLIO

16.24.4 RECENT NEWS/DEVELOPMENTS

16.25 LA RENON HEALTHCARE PVT. LTD.

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

16.26 MADRIGAL PHARMACEUTICALS

16.26.1 COMPANY SNAPSHOTS

16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENT

16.27 NOVO NORDISK A/S

16.27.1 COMPANY SNAPSHOT

16.27.2 REVENUE ANALYSIS

16.27.3 PIPELINE PRODUCT PORTFOLIO

16.27.4 RECENT DEVELOPMENT

16.28 NOVOMEDIX

16.28.1 COMPANY SNAPSHOT

16.28.2 PIPELINE PRODUCT PORTFOLIO

16.28.3 RECENT DEVELOPMENT

16.29 PILANT THERAPEUTICS, INC.

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PIPELINE PRODUCT PORTFOLIO

16.29.4 RECENT NEWS

16.3 PFIZER INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 REVENUE ANALYSIS

16.30.3 PIPELINE PRODUCT PORTFOLIO

16.30.4 RECENT DEVELOPMENT/NEWS

16.31 SAGIMET BIOSCIENCES

16.31.1 COMPANY SNAPSHOTS

16.31.2 REVENUE ANALYSIS

16.31.3 1.1.4 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT/NEWS

16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.32.1 COMPANY SNAPSHOT

16.32.2 REVENUE ANALYSIS

16.32.3 PIPELINE PRODUCT PORTFOLIO

16.32.4 PRODUCT PORTFOLIO

16.32.5 RECENT DEVELOPMENT

16.33 TVARDI THERAPEUTICS

16.33.1 COMPANY SNAPSHOT

16.33.2 PIPELINE PRODUCT PORTFOLIO

16.33.3 RECENT DEVELOPMENT/NEWS

16.34 VERTEX PHARMACEUTICALS INCORPORATED

16.34.1 COMPANY SNAPSHOT

16.34.2 REVENUE ANALYSIS

16.34.3 PRODUCT PORTFOLIO

16.34.4 RECENT DEVELOPMENT

16.35 VIKING THERAPEUTICS

16.35.1 COMPANY SNAPSHOT

16.35.2 REVENUE ANALYSIS

16.35.3 PIPELINE PRODUCT PORTFOLIO

16.35.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表のリスト

TABLE 1 ASIA-PACIFIC INCIDENCE OF CIRRHOSIS BY GENDER (2019)

TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS

TABLE 3 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 7 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 9 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 10 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 12 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 13 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 16 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 17 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 19 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 20 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 22 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 23 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 24 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 26 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 27 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 78 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 80 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 81 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 83 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 84 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 86 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 88 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 89 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 91 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 92 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 94 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 95 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 97 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 98 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 99 ASIA-PACIFIC MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 ASIA-PACIFIC BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 103 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 ASIA-PACIFIC LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 ASIA-PACIFIC ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 ASIA-PACIFIC LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 ASIA-PACIFIC PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 ASIA-PACIFIC CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 ASIA-PACIFIC STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 ASIA-PACIFIC GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 ASIA-PACIFIC HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 113 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 114 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 118 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 121 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 124 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 CHINA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 128 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 130 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 131 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 133 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 134 CHINA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 CHINA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 136 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 138 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 139 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 141 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 142 CHINA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 CHINA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 144 CHINA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 145 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 147 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 148 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 149 CHINA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 CHINA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 153 CHINA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 CHINA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 CHINA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 CHINA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 CHINA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 CHINA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 CHINA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 CHINA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 CHINA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 CHINA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 163 CHINA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 164 CHINA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 CHINA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 CHINA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 CHINA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 168 CHINA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 CHINA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 CHINA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 171 CHINA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 CHINA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 CHINA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 CHINA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 178 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 180 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 181 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 183 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 184 JAPAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 JAPAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 186 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 188 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 189 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 191 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 192 JAPAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 JAPAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 194 JAPAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 195 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 197 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 198 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 199 JAPAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 JAPAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 203 JAPAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 JAPAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 JAPAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 JAPAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 JAPAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 JAPAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 JAPAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 JAPAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 JAPAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 213 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 JAPAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 JAPAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 JAPAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 218 JAPAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 JAPAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 221 JAPAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 JAPAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 224 JAPAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 INDIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 228 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 230 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 231 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 233 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 234 INDIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 INDIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 236 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 238 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 239 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 241 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 242 INDIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 INDIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 244 INDIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 245 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 247 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 248 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 249 INDIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 INDIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 253 INDIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 INDIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 INDIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 INDIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 INDIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 INDIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 INDIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 INDIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 INDIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 INDIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 263 INDIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 264 INDIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 INDIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 INDIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 INDIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 268 INDIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 INDIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 INDIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 271 INDIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 INDIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 INDIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 274 INDIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 278 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 280 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 281 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 283 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 284 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 286 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 288 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 289 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 291 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 292 SOUTH KOREA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 SOUTH KOREA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 294 SOUTH KOREA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 295 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 297 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 298 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 299 SOUTH KOREA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 SOUTH KOREA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 303 SOUTH KOREA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 SOUTH KOREA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 SOUTH KOREA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 SOUTH KOREA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 SOUTH KOREA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 SOUTH KOREA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 SOUTH KOREA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 SOUTH KOREA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 SOUTH KOREA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 313 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 314 SOUTH KOREA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 SOUTH KOREA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 SOUTH KOREA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 318 SOUTH KOREA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 SOUTH KOREA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 321 SOUTH KOREA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 SOUTH KOREA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 324 SOUTH KOREA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 328 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 330 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 331 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 333 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 334 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 336 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 338 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 339 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 341 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 342 AUSTRALIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 AUSTRALIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 344 AUSTRALIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 345 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 347 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 348 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 349 AUSTRALIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 AUSTRALIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 353 AUSTRALIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 AUSTRALIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 AUSTRALIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 AUSTRALIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 AUSTRALIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 AUSTRALIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 AUSTRALIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 AUSTRALIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 AUSTRALIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 363 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 364 AUSTRALIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 AUSTRALIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 AUSTRALIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 368 AUSTRALIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 AUSTRALIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 371 AUSTRALIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 AUSTRALIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 374 AUSTRALIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 378 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 380 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 381 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 383 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 384 SINGAPORE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 SINGAPORE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 386 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 388 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 389 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 391 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 392 SINGAPORE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SINGAPORE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 394 SINGAPORE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 395 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 397 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 398 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 399 SINGAPORE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SINGAPORE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 403 SINGAPORE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 SINGAPORE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 SINGAPORE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 SINGAPORE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 SINGAPORE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 SINGAPORE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 SINGAPORE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 SINGAPORE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 SINGAPORE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 413 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 414 SINGAPORE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 SINGAPORE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 SINGAPORE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 418 SINGAPORE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 SINGAPORE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 421 SINGAPORE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 SINGAPORE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 424 SINGAPORE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 427 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 428 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 430 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 431 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 433 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 434 THAILAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 THAILAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 436 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 438 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 439 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 441 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 442 THAILAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 THAILAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 444 THAILAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 445 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 447 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 448 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 449 THAILAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 THAILAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 453 THAILAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 THAILAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 THAILAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 THAILAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 THAILAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 THAILAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 THAILAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 THAILAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 461 THAILAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 462 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 463 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 464 THAILAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 THAILAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 THAILAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 468 THAILAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 THAILAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 470 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 471 THAILAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 THAILAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 474 THAILAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 475 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 478 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 479 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 480 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 481 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 483 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 484 INDONESIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 485 INDONESIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 486 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 488 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 489 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 491 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 492 INDONESIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 INDONESIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 494 INDONESIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 495 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 496 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 497 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 498 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 499 INDONESIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 500 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 INDONESIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 503 INDONESIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 INDONESIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 505 INDONESIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 506 INDONESIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 507 INDONESIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 INDONESIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 INDONESIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 INDONESIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 INDONESIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 512 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 513 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 514 INDONESIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 INDONESIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 516 INDONESIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 518 INDONESIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 519 INDONESIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 520 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 521 INDONESIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 INDONESIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 524 INDONESIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 527 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 528 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 530 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 531 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 533 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 534 MALAYSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 MALAYSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 536 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 538 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 539 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 541 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 542 MALAYSIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 MALAYSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 544 MALAYSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 545 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 547 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 548 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 549 MALAYSIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 MALAYSIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 553 MALAYSIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 MALAYSIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 MALAYSIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 MALAYSIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 MALAYSIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 MALAYSIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 MALAYSIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 MALAYSIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 MALAYSIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 562 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 563 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 564 MALAYSIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 MALAYSIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 MALAYSIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 568 MALAYSIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 569 MALAYSIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 570 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 571 MALAYSIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 MALAYSIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 574 MALAYSIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 575 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 576 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 578 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 579 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 580 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 581 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 582 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 583 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 584 TAIWAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 585 TAIWAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 586 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 588 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 589 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 591 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 592 TAIWAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 TAIWAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 594 TAIWAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 595 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 597 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 598 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 599 TAIWAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 600 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 TAIWAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 603 TAIWAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 TAIWAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 605 TAIWAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 TAIWAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 TAIWAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 TAIWAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 TAIWAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 TAIWAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 TAIWAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 613 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 614 TAIWAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 TAIWAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 TAIWAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 618 TAIWAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 TAIWAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 620 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 621 TAIWAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 TAIWAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 624 TAIWAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 627 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 628 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 630 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 631 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 632 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 633 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 634 NEW ZEALAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 NEW ZEALAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 636 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 638 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 639 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 641 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 642 NEW ZEALAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 643 NEW ZEALAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 644 NEW ZEALAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 645 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 647 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 648 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 649 NEW ZEALAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 650 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 651 NEW ZEALAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 652 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 653 NEW ZEALAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 654 NEW ZEALAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 655 NEW ZEALAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 656 NEW ZEALAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 657 NEW ZEALAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 NEW ZEALAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 NEW ZEALAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 NEW ZEALAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 661 NEW ZEALAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 662 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 663 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 664 NEW ZEALAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 NEW ZEALAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 666 NEW ZEALAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 667 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 668 NEW ZEALAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 669 NEW ZEALAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 670 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 671 NEW ZEALAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 672 NEW ZEALAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 673 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 674 NEW ZEALAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 675 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 676 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 677 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 678 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 679 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 680 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 681 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 682 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 683 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 684 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 685 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 686 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 688 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 689 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 690 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 691 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 692 PHILIPPINES INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 PHILIPPINES INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 694 PHILIPPINES INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 695 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 696 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 697 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 698 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 699 PHILIPPINES MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 700 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 701 PHILIPPINES BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 702 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 703 PHILIPPINES SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 704 PHILIPPINES LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 705 PHILIPPINES ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 706 PHILIPPINES LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 707 PHILIPPINES PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 708 PHILIPPINES CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 709 PHILIPPINES STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 710 PHILIPPINES GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 711 PHILIPPINES HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 713 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 714 PHILIPPINES HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 715 PHILIPPINES AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 716 PHILIPPINES GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 717 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 718 PHILIPPINES MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 PHILIPPINES FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 720 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 721 PHILIPPINES HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 722 PHILIPPINES SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 723 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 724 PHILIPPINES RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 726 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 727 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 728 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 729 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 730 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 731 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 732 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 733 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 734 VIETNAM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 735 VIETNAM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 736 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 737 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 738 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 739 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 741 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 742 VIETNAM INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 743 VIETNAM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 744 VIETNAM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 745 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 746 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)

TABLE 747 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)

TABLE 748 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)

TABLE 749 VIETNAM MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 750 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 VIETNAM BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 752 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 753 VIETNAM SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 754 VIETNAM LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 755 VIETNAM ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 756 VIETNAM LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 757 VIETNAM PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 758 VIETNAM CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 759 VIETNAM STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 760 VIETNAM GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 761 VIETNAM HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 762 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)

TABLE 763 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)

TABLE 764 VIETNAM HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 765 VIETNAM AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 VIETNAM GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 768 VIETNAM MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 769 VIETNAM FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 770 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 771 VIETNAM HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 VIETNAM SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 774 VIETNAM RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 775 REST OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

図表一覧

FIGURE 1 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET IN 2025-2032

FIGURE 13 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

FIGURE 14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 15 STRATEGIC DECISIONS

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET

FIGURE 17 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 18 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 19 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 20 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 21 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024

FIGURE 22 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)

FIGURE 23 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)

FIGURE 24 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 25 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024

FIGURE 26 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)

FIGURE 27 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)

FIGURE 28 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 29 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024

FIGURE 30 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 31 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 32 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 33 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024

FIGURE 34 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 35 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)

FIGURE 36 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024

FIGURE 38 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 39 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 40 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 42 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Asia-Pacific liver fibrosis treatment market size was valued at USD 3.77 billion in 2024.
The Asia-Pacific liver fibrosis treatment market is to grow at a CAGR of 12.9% during the forecast period of 2025 to 2032.
The liver fibrosis treatment market is segmented into five notable segments based on treatment type, stages, indication, end user, and distribution channel. On the basis of treatment type, the market is segmented into medication and surgery/therapy. on the basis of stages, the market is segmented into F2, F1, F3, and F4, on the basis of indication, the market is segmented into non-alcoholic steatohepatitis (Nash), hepatitis B & C-induced fibrosis, alcoholic liver disease (ALD), autoimmune liver diseases, genetic disorders, and others. on the basis of gender, the market is segmented into male and female. on the basis of end user, the market is segmented into hospitals, specialty clinics, clinics, ambulatory and research centers, and others. on the basis of distribution channel, the market is segmented into direct tender and retail sales.
Companies such as Gilead Sciences, Inc. (U.S.),AbbVie Inc. (U.S.),Merck & Co., Inc. (U.S.),Novartis AG (Switzerland), Intercept Pharmaceuticals, Inc. (U.S.)are the major companies in the europe liver fibrosis treatment.
In October 2024, Intercept Pharmaceuticals, Inc discussed their ongoing efforts to explore racial differences and disparities in Primary Biliary Cholangitis (PBC) care. The company is addressing how various populations may face different challenges in the diagnosis, treatment, and management of PBC. By exploring these disparities, Intercept aims to improve access to care and treatment outcomes for all patients, potentially reducing barriers to effective treatment of liver diseases, including fibrosis.
The countries covered in the global liver fibrosis treatment are China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, rest of Asia-Pacific.
China leads the liver fibrosis treatment market in Asia-Pacific, driven by its robust healthcare infrastructure, high prevalence of liver-related diseases, and strong focus on early diagnosis and intervention strategies
China region is expected to witness the highest growth rate in the Asia-Pacific liver fibrosis treatment, driven by increasing obesity prevalence, rising healthcare investments, and growing awareness about weight management solutions.
The primary challenges include long-term follow-ups associated with liver fibrosis treatment, high costs, limited curative options, and patient adherence issues.
The treatment type segment is expected to dominate the Asia-Pacific liver fibrosis treatment market in 2025 due to increasing demand for effective therapies, ongoing clinical trials, and rising approvals of novel drugs.
Increasing Prevalence of Liver Diseases, is emerging as a pivotal trend driving the Asia-Pacific liver fibrosis treatment .
The major factors driving the growth of Asia-Pacific liver fibrosis treatment are rising consumption of alcohol, rising liver transplantation rates, and growing incidence of non-alcoholic fatty liver disease (NAFLD) & NASH.

関連ページを閲覧する

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future